Do not inj. Follow-up on any symptom indicative of intussusception (severe abdominal pain, persistent vomiting, bloody stools, abdominal bloating &/or high fever). Carefully consider potential benefits & risks before administration in infants who have known or suspected immunodeficiency. Caution to individuals w/ immunodeficient close contacts. Contacts of recent vaccinees should observe personal hygiene. Consider potential risk of apnoea & the need for resp monitoring for 48-72 hr when administering primary immunisation series to very premature infants & those w/ history of resp immaturity. Protective immune response may not be elicited in all vaccinees. Does not protect against gastroenteritis due to other pathogens than rotavirus. No available data on use for post-exposure prophylaxis. No data on safety, immunogenicity or efficacy when Rotarix is administered for the 1st dose & another rotavirus vaccine is administered for the 2nd dose or vice versa. Patients w/ rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this vaccine. Contains phenylalanine 0.15 mcg/dose; may be harmful for patients w/ phenylketonuria. Contains Na 34 mg/dose. Not for use in adults. Should not be used in childn >24 wk of age. No data on safety & efficacy in infants w/ GI illnesses or growth retardation.
Sign Out
